GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-02-24| Funding

Plexium Bags $102 Million for Targeted Protein Degraders

by Joy Lin
Share To

Plexium sees the promise of using small molecules to destroy rather than inhibit disease-causing proteins – and now it has $102 million to bring candidates into clinical trials. 

Lining its pipeline is a molecular glue that degrades the IKZF2 transcription factor, which helps regulate lymphocyte development. 

Plexium is also assessing selective degraders of CDK2, a cell cycle protein, and SMARCA2, a gene regulator in neuronal development. 

The San Diego, California-based preclinical biotech launched in 2019 with $28 million in Series A financing. To date, it has raised almost $200 million. This includes an oncology-focused drug discovery collab with Amgen that could earn Plexium $500 million in total. 

Related Article: Expanding Deals and Investments Underscore Burgeoning Market of Targeted Protein Degradation

 

How Do Targeted Protein Degraders Work?

 

Targeted protein degraders mediate the labeling of a target protein for destruction. 

The degraders, which could be a small molecule, could bring a target protein and a E3 ubiquitin ligase together. Imagine a sort of molecular glue that encourages interactions between two targets that don’t normally interact, and subsequently labels the target for degradation via proteasome. Small molecules with this function are called proteolysis targeting chimeras, or PROTACs. 

Other small molecules called monovalent protein degraders could change the surface of a target protein to make it easier for the cell degradation machinery to recognize and destroy the target. 

Plexium believes its high-throughput cell-based screening platform could discover new protein degraders from molecular glues to monovalent degraders, while also identifying new E3 ligases. This could open opportunities to address undruggable targets, the company said. 

Protein Degraders in the Clinic

 

As Plexium hopes to go clinical, several companies are already taking their products through human trials. Ranok Therapeutics was recently cleared by the US FDA to conduct a Phase 1/2 trial for its BRD4-selective degrader in advanced solid tumors and lymphomas. 

Meanwhile, Arvinas Therapeutics has reported that its androgen receptor degrader is showing responses in prostate cancer patients with a specific mutation. Arvinas is hoping to get accelerated approval once data on 100 patients with the mutation comes out. In 2019, the company was the first to take a protein degrader into a clinical trial.  

Related Article: Eli Lilly, Lycia Partnership Signifies the Growing Targeted Protein Degradation Market

 

Details of the $102 Million Funding Round 

 

The oversubscribed round was led by BVF Partners, L.P. and TCG X, with participation from four new investors Softbank Vision Fund 2, RA Capital Management, Surveyor Capital (a Citadel company), and Pappas Capital. Seven existing investors including Lux Capital and Pivotal bioVenture Partners also took part. 

In connection with the financing, Cariad Chester, a partner at TCG X, has joined Plexium’s board.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
JPM 2025 Looks at the Cell and Gene Therapy Landscape – Autoimmune, Cancer, and Chronic Diseases are Front and Center
2025-01-21
Cecile Richards’s Battle with Glioblastoma
2025-01-21
Neuro, Pain, and Cancer Top the List at JPM 2025 Healthcare Conference
2025-01-17
LATEST
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
What the PlayStation Network Outage Can Teach the Biotech Industry
2025-02-08
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top